Introduction
============

Anthocyanins, a subclass of the flavonoids, are found in foods such as berries and fruits and information regarding their content in food can be found in an online phenol-explorer ([@B21]). Anthocyanins have been shown in previous studies to have a number of positive health effects, such as improving the blood lipid profile ([@B22]; [@B17]), and also fasting serum glucose and glycosylated hemoglobin (HbA1c) in diabetic patients ([@B17]; [@B36]), and have anti-inflammatory effects ([@B35]; [@B30]; [@B29]). Anthocyanins can improve endothelial and vascular function ([@B25], [@B26], [@B24]), and can cross the blood--brain barrier ([@B5]) and thus may reduce neurodegenerative and cerebrovascular changes and possibly protect against cognitive decline and dementia. Interestingly, some studies have found that food-based anthocyanins can improve memory functioning in older adults with mild cognitive impairment (MCI; [@B15],[@B16]; [@B12]). However, these studies were based on relatively small samples, and had a short duration. In addition, food-based anthocyanin supplementation leads to heterogeneity, i.e., variations in types of food sources, concentration, and dose of anthocyanins.

In this exploratory open-label pilot study, we aimed as a primary endpoint to examine potential changes in dementia-relevant mechanisms after 16 weeks of treatment with purified anthocyanin containing capsules, in people with increased risk of dementia. As a secondary endpoint we also explored the potential change in a battery of cognitive tests.

Materials and Methods {#s1}
=====================

Material
--------

Participants were recruited from the outpatient Memory and Cardiology clinics at Stavanger University Hospital in Norway during 2015 and 2016. Eligible for this study were patients with MCI or mild dementia and/or stable non-obstructive coronary artery disease (CAD). Potential participants identified at the respective outpatient clinics were contacted for a telephone interview by a study doctor, regarding inclusion and exclusion criteria. Participants were also recruited from the dementia disease initiation (DDI) study ([@B7]). Inclusion criteria were age ≥50 years and being on stable medication, including nutraceuticals for the past 3 months, and either (a) confirmed CAD without physiologically significant stenosis evaluated by coronary angiography, or (b) having MCI or mild dementia according to ICD 10 ([@B34]).

Exclusion criteria were moderate to severe dementia \[operationalized as a mini-mental status exam (MMSE) ([@B8]) score \< 24\], clinically significant depression \[15--item Geriatric Depression Scale (GDS-15) ([@B19]) score ≥ 7\], unstable CAD, heart failure in need of treatment, having taken Medox^®^ during the past 3 months, using Warfarin, heparin or non-vitamin K antagonist oral anticoagulants (NOAC), inflammatory illnesses such as rheumatoid arthritis and other severe illness with \<5 years expected survival. Any treatment with vitamins, minerals or nutraceuticals had to have remained stable for the last 3 months prior to inclusion and during the study. Healthy normal controls (NC) (*n* = 20) recruited from the staff at Stavanger University Hospital and through acquaintances, were ≥50 years, had stable medication, and had not been taking Medox^®^ for the last 3 months. This group provided blood samples at inclusion and 16 weeks later, but did not take Medox^®^ or other interventions, and did not perform the cognitive test battery. The rationale for including this comparison group was to have a reference group with respect to any observed changes in the blood analyses in the intervention group.

Ethics Statement
----------------

All participants provided written informed consent, and the study has been approved by the Regional Ethics Committee (Approval 2014/1966). The study has been registered at [ClinicalTrials.gov](http://www.ClinicalTrials.gov) (NCT02409446).

Intervention, Design, and Assessment
------------------------------------

### Intervention

The participants were given open-label Medox^®^ capsules, provided free of charge by the manufacturer Medpalett AS, Sandnes, Norway. Medox^®^ capsules, which contain specific quantities of natural purified anthocyanins from bilberry (*Vaccinium myrtillus*) and blackcurrant (*Ribes nigrum*), have been used previously in human studies ([@B13]). The production of the Medox^®^ capsule ([@B11]), and its anthocyanin content ([@B22]) have been described previously.

The capsules were dispensed at inclusion in the study, and the participants were instructed to consume two 80 mg anthocyanin capsules twice daily for a total daily intake of 320 mg anthocyanins for 16 weeks. This dosage was chosen because it has previously been shown to have biological effects ([@B22]; [@B39]; [@B17]) and found to be safe in use ([@B22]). A review found that doses up to 640 mg/day showed no adverse events ([@B32]).

Participants were instructed to maintain their dietary and lifestyle habits in order to avoid interferences in the study results.

### Design and Assessment

At inclusion, all participants underwent a physical examination, including standardized blood pressure measurement, electrocardiogram (ECG), and blood tests. In addition a cognitive test battery (see below) was administered, including the MMSE and GDS-15. Following standardized procedures, participants provided blood samples in the morning after having been fasting for at least 8 h, before and after 16 weeks of treatment. They were contacted by telephone after 8 weeks regarding safety and compliance.

Blood Sampling and Analyses
---------------------------

Blood was collected, centrifugated, and stored at −80 °C until analysis according to standardized procedures. The serum samples were analyzed for lipids (total cholesterol, triglycerides, HDL- and LDL cholesterol) and fasting glucose using Architect c16000 TM (Abbott Diagnostics, Chicago, IL, United States) and HbA1c using Variant II turbo (BioRad, Hercules, CA, United States) at Stavanger University Hospital.

Markers of inflammation were analyzed after completion of the study by The Lipid Research Group, Department of Clinical Sciences, University of Bergen, Bergen, Norway. Concentrations of cytokines were measured in serum using the Bio-Plex Pro^TM^ Human Cytokine 8-plex assay (Cat.: M50000007A) which included GM-CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, and TNF-α, in addition to five Bio-Plex Pro Human Cytokine single-plexes: MCP-1 (Cat.: 171B5021M), RANTES (Cat.: 171B5025M), G-CSF (Cat.: 171B5017M), IL-17 (Cat.: 171B5014M), and IL-Iβ (Cat.:171B5001M). All plexes were manufactured by Bio-Rad (Hercules, CA, United States). The cytokines were detected by the Bio-Plex^TM^ 200 System and determined with the Bio-Plex Manager Software 6.1. The samples were prepared as described in the protocol (Cat.: 10014905) with a dilution factor of three.

Anthocyanin metabolites were measured in plasma after completion of the study at Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King's College London, using a method based on microelution solid phase extraction followed by liquid chromatography and mass spectrometry, using authentic standards, as previously described with some modifications ([@B6]). The detection of plasma (poly)phenol metabolites was performed on a Exactive^TM^ Orbitrap Mass Spectrometer (Thermo Scientific, Waltham, CA, United States) after separation on an Accela 1250 pump UHPLC system (Thermo Scientific, Waltham, CA, United States). The autosampler injected 5 μL of each sample in a Zorbax Eclipse Plus RRHD column 2.1 mm × 50 mm, 1.8 m with a compatible Eclipse Plus guardcolumn 2.1 mm × 5 mm, 1.8 m (Agilent, Waldbronn, Germany). The mobile phase consisted of 0.1% HCOOH (solvent A) and acetonitrile with 0.1% HCOOH (solvent B) in a 10 min gradient program. Quantification analysis of the plasma (poly)phenols was done using Xcalibur 2.2 (Thermo Scientific, Waltham, CA, United States).

Cognitive Tests
---------------

Verbal memory function was assessed using the Norwegian adaptation of the Ten Word List Learning and Recall from the CERAD battery ([@B20]), a three part test; word list learning, word list delayed recall, and word list delayed recognition.

Executive functioning was assessed by the Trail Making Test (TMT) A and B ([@B23]) and Stroop Golden ([@B9]). The Trail Making Tests A and B are tests of psychomotor speed and attention shifting ([@B2]), while Stroop Golden is a test used to evaluate cognitive speed and inhibition ([@B27]).

Safety
------

Participants were contacted by phone at week 8 to ask about potential side-effects and adverse events (AE).

The safety blood tests included hemoglobin, thrombocytes, kidney function and liver function tests, which were measured at both baseline and study-end.

Compliance
----------

Participants were contacted by phone at week 8 and asked about adherence to the protocol. Specifically, they were asked whether they had been taking Medox^®^ capsules as instructed, and they were reminded about keeping the empty blister packages. Protocol adherence was also assessed by collecting and counting the empty blister packages and left-over capsules at study-end.

Statistical Analyses
--------------------

Descriptive statistics are presented as medians and interquartile ranges (IQR), and illustrated using Box plots. Most data were not normally distributed and thus the main analyses were non-parametric. The Mann--Whitney *U* test and the Chi-square test were used for between-group comparisons. Changes from baseline to follow-up at 24 weeks within groups were analyzed with the Wilcoxon Signed Rank test. For all tests *p* ≤ 0.05 was considered statistically significant.

Supplementary parametric analyses were performed, from which we present means, standard deviations (SD), and *p*-values from paired and independent samples *t*-tests.

The IBM SPSS statistical package version 24 was used for all statistical analyses.

Results
=======

During the period May 2015 to September 2016, 33 participants started anthocyanin supplementation, of whom 27 (8 MCI and 19 CAD) completed the study (6 were excluded for administrative and logistical reasons) ([Figure 1](#F1){ref-type="fig"}). The NC were included in the period December 2016 to February 2017. No subjects with mild dementia were included.

![Enrolment of participants. N, number.](fgene-10-00536-g001){#F1}

###### 

Baseline characteristics.

                                          Active (*n* = 27)   Controls (*n* = 20)
  --------------------------------------- ------------------- ---------------------
  Women, count (%)                        9 (33)              11 (55)
  Age (years)                             61 (55--70)         58 (55--62)
  CAD, count (%)                          19 (70)             
  Education (years)                       11.5 (10--14)       
  BMI                                     27.7 (26.0--30.3)   
  Lipid lowering therapy, count (%)       19 (70)             
  Acetylsalicylic acid, count (%)         17 (63)             
  Oral antidiabetic treatment count (%)   3 (11)              
  Dietary supplement, count (%)           18 (67)             

CAD, coronary artery disease; BMI, body mass index; IQR, interquartile range.

###### 

Changes from baseline to 16 weeks follow-up in serum variables, for participants with supplementation (active) and for control participants.

                                 Active (*n* = 27)                       Control (*n* = 20)             Active vs. control
  ------------------------------ --------------------- ----------------- ---------------------- ------- --------------------
  **Cholesterol (mmol/L)**                             Cholesterol                                      
  Pre                            4.0 (3.1 to 5.5)                        5.1 (4.5 to 5.5)               
  Post                           4.6 (3.3 to 6.0)                        5.1 (4.6 to 5.6)               
  Diff                           0.2 (0.1 to 0.7)      0.009             0.1 (−0.2 to 0.5)      0.29    0.34
  **HDL (mmol/L)**                                     HDL                                              
  Pre                            1.2 (1.0 to 1.4)                        1.5 (1.1 to 1.7)               
  Post                           1.2 (1.1 to 1.5)                        1.4 (1.2 to 1.8)               
  Diff                           0.0 (−0.1 to 0.1)     0.81              0.1 (−0.1 to 0.1)      0.21    0.23
  **LDL (mmol/L)**                                                       LDL*^n^*^=19^                  
  Pre                            2.4 (1.8 to 3.9)                        3.3 (2.9 to 3.9)               
  Post                           3.0 (1.8 to 4.3)                        3.3 (2.8 to 4.0)               
  Diff                           0.1 (−0.1 to 0.3)     0.21              0.0 (−0.1 to 0.4)      0.62    0.72
  **Triglycerides (mmol/L)**                           Triglycerides                                    
  Pre                            1.0 (0.7 to 1.4)                        0.9 (0.6 to 1.3)               
  Post                           1.0 (0.7 to 1.7)                        0.9 (0.6 to 1.8 )              
  Diff                           0.1 (0.7 to 1.7)      0.016             0.0 (−0.1 to 0.4)      0.072   0.84
  **Fasting glucose (mmol/L)**                         Fasting glucose                                  
  Pre                            5.4 (4.9 to 5.6)                        5.3 (5.0 to 5.6)               
  Post                           5.5 (5.3 to 6.3)                        5.0 (4.8 to 5.7)               
  Diff                           0.2 (−0.1 to 0.4)     0.058             −0.2 (−0.4 to −0.03)   0.009   0.71
  **HbA1c (%)**                                                          HbA1c                          
  Pre                            5.8 (5.6 to 6.1)                        5.6 (5.4 to 5.8)               
  Post                           5.8 (5.6 to 6.1)                        5.4 (5.2 to 5.6)               
  Diff                           0.0 (−0.1 to 0.1)     0.87              −0.05 (−0.2 to 0.0)    0.057   0.11
  **IL-8 (mmol/L)**                                    IL-8                                             
  Pre                            9.0 (7.7 to 10.3)                       7.5 (7.2 to 8.4)               
  Post                           9.2 (6.9 to 11.1)                       7.8 (7.2 to 8.9)               
  Diff                           0.0 (−1.5 to 1.2)     0.80              0.2 (−1.0 to 1.5)      0.79    0.41
  **MCP-1 (pg/mL)**                                    MCP-1                                            
  Pre                            42.2 (10.3 to 59.4)                     51.7 (40.9 to 70.2)            
  Post                           41.3 (11.1 to 60.2)                     52.8 (45.1 to 93.7)            
  Diff                           0.0 (−5.4 to 1.7)     0.55              1.9 (0.2 to 17.5)      0.014   0.95
  **RANTES (pg/mL)**                                   RANTES                                           
  Pre                            9206 (8172 to 9833)                     8800 (8370 to 9761)            
  Post                           8918 (8046 to 9942)                     9164 (8651 to 10027)           
  Diff                           −161 (−730 to 677)    0.81              19.09 (−633 to 1105)   0.41    0.003
  **TNFa (pg/mL)**                                     TNFa*^n^*^=19^                                   
  Pre                            10.1 (7.8 to 13.3)                      6.5 (6.1 to 10.9)              
  Post                           9.9 (6.5 to 13.9)                       8.0 (5.8 to 11.4)              
  Diff                           0.9 (−2.8 to 2.9)     0.74              −0.4 (−1.5 to 3.9)     0.66    0.26

RANTES; CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted); Diff, median difference between baseline and follow up serum measurements; IQR, interquartile range; mmol/L, millimol/liter; pg/mL, picomol/liter.

∗

The within group difference from baseline to study end.

\#

The between group differences for Δ (difference from baseline to study end).

Baseline characteristics are shown in [Table 1](#T1){ref-type="table"}.

Only IL-8, MCP-1, CCL-5/RANTES \[regulated on activation, normal T-cell expressed and secreted (RANTES)\] and TNF were available for statistical analyses, as the other inflammation markers did not reach measurement thresholds. The findings are summarized in [Table 2](#T2){ref-type="table"} and [Supplementary Figures S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}.

The only significant between-group difference was for ΔRANTES (difference from baseline to study end) which decreased in the supplementation group and increased in the NC group ([Table 2](#T2){ref-type="table"}).

When analyzing the groups separately, significant increases were found in total cholesterol and triglycerides in the anthocyanin supplementation group (AG) from baseline to study end ([Table 2](#T2){ref-type="table"}), and MCP-1 which increased in the NC group ([Table 2](#T2){ref-type="table"}).

###### 

Changes from baseline to 16 weeks follow-up in plasma anthocyanin metabolites, for participants with supplementation (active) and for control participants.

                                                       Active (*n* = 27)                  Control (*n* = 20)               Active vs. control
  ---------------------------------------------------- ------------------------ --------- ------------------------ ------- --------------------
  **Methylpyrogallol-*O*-sulfate**                                                                                         
  Pre                                                  33.1 (17.5 to 52.5)                26.2 (10.2 to 67.6)              
  Post                                                 45.5 (24.1 to 104.2)               20.6 (7 to 65.3)                 
  Diff                                                 15.6 (−3.3 to 70.7)      0.068     −1.7 (−23.8 to 13.0)     0.85    0.14
  **Pyrogallol-2-*O*-sulfate**                                                                                             
  Pre                                                  36.4 (17.2 to 110.5)               58.4 (20.4 to 102.4)             
  Post                                                 63.8 (41.5 to 199.1)               35.2 (21.2 to 93.1)              
  Diff                                                 17.5 (−8.3 to 106.4)     0.001     −12.3 (−82.4 to 32.1)    0.41    0.89
  **Protocatechuic acid-3-*O*-sulfate**                                                                                    
  Pre                                                  3.5 (0.3 to 11.1)                  5.4 (1.6 to 10.1)                
  Post                                                 11.0 (5.5 to 26.5)                 6.5 (0.3 to 16.4)                
  Diff                                                 6.2 (0.0 to 21.6)        0.007     0.8 (−6.3 to 10.1)       0.81    0.071
  **1-Methylpyrogallol-*O*-sulfate**                                                                                       
  Pre                                                  44.7 (29.2 to 77.3)                60.8 (34.8 to 123)               
  Post                                                 52.7 (33.6 to 97.2)                71.8 (30.3 to 106)               
  Diff                                                 12.8 (−19.6 to 32.7)     0.14      10.4 (−27.8 to 65.5)     0.60    0.70
  **4-Methylgallic-3-*O*-sulfate**                                                                                         
  Pre                                                  14.0 (5.6 to 23.8)                 13.1 (8.5 to 28.7)               
  Post                                                 12.8 (7.1 to 24.6)                 12.3 (7.3 to 21.1)               
  Diff                                                 1.6 (−7.8 to 14.3)       0.65      −5.5 (−15.6 to 12.0)     0.35    0.25
  **4-Hydroxybenzoic acid-*O*-sulfate**                                                                                    
  Pre                                                  2027 (1211 to 4284)                2664 (1455 to 3764)              
  Post                                                 1704 (772 to 3597)                 1723 (420 to 4354)               
  Diff                                                 −97 (−1039 to 234)       0.14      −924 (−2691 to 1046)     0.26    0.67
  **4-Hydroxyhippuric acid**                                                                                               
  Pre                                                  164 (93 to 272)                    145 (117 to 275)                 
  Post                                                 123 (94 to 283)                    111 (91 to 163)                  
  Diff                                                 6 (−84 to 44)            0.84      −33 (−236 to 33)         0.079   0.21
  **Protocatechuic acid**                                                                                                  
  Pre                                                  57.5 (22.0 to 106.8)               66.6 (35.5 to 127)               
  Post                                                 51.3 (29.4 to 114.2)               48.7 (5.0 to 76.9)               
  Diff                                                 1.6 (−49.7 to 51.3)      0.75      −22.0 (−85.2 to 17.2)    0.049   0.057
  **Pyrogallol-1-*O*-sulfate**                                                                                             
  Pre                                                  25.6 (15.3 to 61.2)                55.1 (25.3 to 106.5)             
  Post                                                 52.9 (25.5 to 97.6)                63.8 (41.4 to 94.4)              
  Diff                                                 18.8 (1.5 to 68.4)       0.006     −2.9 (−36.3 to 45.7)     0.85    0.093
  **3,4-Dihydroxyphenylacetic acid**                                                                                       
  Pre                                                  174 (100 to 237)                   122 (85 to 197)                  
  Post                                                 106 (84 to 213)                    98 (75 to 163)                   
  Diff                                                 −26 (−135 to 69)         0.20      −33 (−67 to 2)           0.044   0.97
  **Catechol-*O*-sulfate**                                                                                                 
  Pre                                                  5518 (2718 to 8056)                5986 (4284 to 7527)              
  Post                                                 4640 (3183 to 7843)                4690 (3576 to 5627)              
  Diff                                                 367 (−2569 to 1608)      0.61      −937 (−3502 to 2010)     0.25    0.67
  **Vanillic acid-4-*O*-sulfate**                                                                                          
  Pre                                                  30.6 (9.5 to 47.8)                 24.6 (9.6 to 39.6)               
  Post                                                 26.2 (9.8 to 42.3)                 22.6 (7.9 to 34.7)               
  Diff                                                 −6.5 (−27.6 to 10.8)     0.20      −5.2 (−15.0 to 23.8)     1.0     0.41
  **3-Hydroxyhippuric acid**                                                                                               
  Pre                                                  709 (191 to 3060)                  451 (269 to 1343)                
  Post                                                 339 (63 to 1233)                   162 (35 to 599)                  
  Diff                                                 −503 (−1246 to −55)      0.002     −183 (−1117 to 196)      0.10    0.28
  ***p*-Coumaric acid-4-*O*-β-*D*-glucuronide**                                                                            
  Pre                                                  0.29 (0.00 to 0.52)                0.23 (0.00 to 0.46)              
  Post                                                 0.21 (0.11 to 0.41)                0.17 (0.00 to 0.30)              
  Diff                                                 −0.07 (−0.26 to 0.24)    0.92      0.01 (−0.20 to 0.20)     0.94    0.84
  **Isovanillic acid-3-*O*-sulfate**                                                                                       
  Pre                                                  2.3 (0.0 to 8.3)                   5.5 (0.0 to 19.1)                
  Post                                                 2.8 (0.0 to 11.3)                  5.7 (0.3 to 14.4)                
  Diff                                                 0.0 (−3.5 to 11.3)       0.90      −1.1 (−10.6 to 3.6)      0.50    0.48
  **Catechol-*O*-1-glucuronide**                                                                                           
  Pre                                                  1.7 (0.0 to 9.2)                   2.2 (0.1 to 8.0?)                
  Post                                                 4.6 (1.6 to 14.2)                  1.1 (0.1 to 6.6)                 
  Diff                                                 1.5 (−1.5 to 8.8)        0.075     0.1 (−2.2 to 1.7)        0.97    0.14
  **Ferulic acid-4-*O*-β-*D*-glucuronide**                                                                                 
  Pre                                                  4.3 (0.4 to 33.4)                  7.7 (1.0 to 19.4)                
  Post                                                 19.4 (2.6 to 59.3)                 5.8 (1.1 to 21.5)                
  Diff                                                 5.5 (0.2 to 31.4)        0.013     −0.3 (−5.9 to 15.4)      0.98    0.064
  **Hippuric acid**                                                                                                        
  Pre                                                  17680 (9444 to 55008)              24075 (11958 to 39646)           
  Post                                                 15225 (8654 to 40673)              12211 (11086 to 28936)           
  Diff                                                 −3572 (−18398 to 1041)   0.068     −2788 (−15907 to 4975)   0.33    0.68
  **4-Methylcatechol-*O*-sulfate**                                                                                         
  Pre                                                  1630 (815 to 3580)                 1209 (753 to 1889)               
  Post                                                 1228 (691 to 2722)                 997 (647 to 1899)                
  Diff                                                 −182 (−1087 to 733)      0.47      −221 (−617 to 255)       0.28    0.95
  **4-Hydroxybenzaldehyde**                                                                                                
  Pre                                                  72.6 (40.3 to 130)                 81.2 (58.4 to 105)               
  Post                                                 53.5 (48.9 to 93.3)                48.7 (39.5 to 75.5)              
  Diff                                                 −24.8 (−56.1 to 6.5)     0.029     −34.3 (−52.8 to −6.8)    0.019   0.78
  **Ferulic acid-4-*O*-sulfate**                                                                                           
  Pre                                                  2.3 (0.5 to 7.0)                   4.0 (0.0 to 12.3)                
  Post                                                 1.9 (0.8 to 23.8)                  6.1 (1.6 to 9.7)                 
  Diff                                                 0.5 (−2.9 to 21.1)       0.20      1.1 (−7.7 to 9.1)        0.55    0.69
  **Dihydroisoferulic acid-3-*O*-sulfate**                                                                                 
  Pre                                                  7.2 (0.0 to 17.5)                  4.9 (0.0 to 14.1)                
  Post                                                 9.2 (2.1 to 23.7)                  7.6 (1.0 to 19.4)                
  Diff                                                 1.0 (−7.5 to 8.6)        0.47      0.9 (−6.9 to 13.0)       0.69    0.94
  **Isoferulic acid-3-*O*-sulfate**                                                                                        
  Pre                                                  1.1 (0.3 to 2.3)                   0.8 (0.4 to 5.7)                 
  Post                                                 4.5 (0.4 to 13.7)                  1.5 (0.3 to 8.6)                 
  Diff                                                 0.6 (−1.7 to 10.2)       0.25      0.4 (−1.6 to 2.4)        0.55    0.67
  **Dihydroisoferulic acid-3-*O*-β-*D*-glucuronide**                                                                       
  Pre                                                  19.1 (7.2 to 45.7)                 25.8 (2.5 to 82.4)               
  Post                                                 20.7 (8.1 to 60.8)                 16.1 (5.4 to 43.4)               
  Diff                                                 1.2 (−15.4 to 34.5)      0.47      −4.9 (−70.9 to 27.7)     0.55    0.31
  **Isoferulic acid-3-*O*-β-*D*-glucuronide**                                                                              
  Pre                                                  22.3 (5.2 to 67.5)                 21.2 (1.8 to 54.6)               
  Post                                                 27.3 (8.5 to 136.4)                21.3 (5.7 to 58.6)               
  Diff                                                 24.4 (−18.0 to 96.2)     0.044     2.7 (−10.1 to 36.8)      0.55    0.21
  **Dihydroferulic acid-4-*O*-sulfate**                                                                                    
  Pre                                                  3.7 (1.2 to 8.3)                   1.9 (0.2 to 3.6)                 
  Post                                                 1.6 (0.9 to 5.1)                   2.7 (1.4 to 5.2)                 
  Diff                                                 −1.5 (−3.1 to −0.3)      0.006     0.8 (−0.9 to 2.9)        0.31    0.010
  **3-(3-hydroxyphenyl)propanoic acid**                                                                                    
  Pre                                                  805 (44 to 2377)                   350 (14 to 1479)                 
  Post                                                 470 (72 to 4306)                   414 (112 to 1624)                
  Diff                                                 29 (−495 to 831)         0.43      36 (−917 to 345)         0.74    0.76
  ***m*-Coumaric acid**                                                                                                    
  Pre                                                  111 (35 to 146)                    84 (63 to 110)                   
  Post                                                 55 (38 to 78)                      58 (53 to 85)                    
  Diff                                                 −62 (−82 to 16)          0.014     −28 (−58 to 2)           0.093   0.33
  ***o*-Coumaric acid**                                                                                                    
  Pre                                                  218 (81 to 356)                    125 (81 to 234)                  
  Post                                                 87 (47 to 158)                     81 (50 to 162)                   
  Diff                                                 −116 (−230 to −35)       \<0.001   −36 (−111 to −1)         0.006   0.019

Diff, median difference between baseline and follow up plasma measurements; IQR, interquartile range; nmol/L = nanomol/liter.

∗

The within group difference from baseline to study end.

\#

The between group differences for Δ (difference from baseline to study end).

No significant changes were found for fasting glucose and HbA1c in the AG group.

A total of 29 plasma anthocyanin metabolites were quantified ([Table 3](#T3){ref-type="table"} and [Supplementary Figure S4](#SM4){ref-type="supplementary-material"}). When comparing the two groups, a statistically significant difference was found for two metabolites (*o*-Coumaric acid and Dihydroferulic acid-4-*O*-Sulfate), which both had a larger decrease in the AG than in the NC group ([Table 3](#T3){ref-type="table"}).

In the AG, there was a statistically significant increase in five of the metabolites (Pyrogallol-2-*O*-sulfate, Protocatechuic acid-3-*O*-sulfate, Pyrogallol-1-*O*-sulfate, Ferulic acid-4-*O*-β-*D*-glucuronide, Isoferulic_acid-3-*O*-β-*D*-glucuronide) and a statistically significant decrease in five other metabolites (3-Hydroxyhippuric acid, 4-Hydroxybenzaldehyde, Dihydroferulic acid-4-*O*-Sulfate, *m*-Coumaric acid, *o*-Coumaric acid) after 16 weeks of anthocyanin consumption in comparison with baseline.

In the NC group, there was a statistically significant decrease in four metabolites (Protocatechuic acid, 3,4-Dihydroxyphenylacetic acid, 4-Hydroxybenzaldehyde and *o*-Coumaric acid), whereas there were no statistically significant increases in any of the metabolites.

###### 

Changes from baseline to 16 weeks follow-up in cognitive variables, for participants with supplementation (active).

                                Active (*n* = 27)       
  ----------------------------- ----------------------- ---------
  **CERAD (points) Learning**                           
  Pre                           20 (16 to 22)           
  Post                          21 (17 to 25)           
  Diff                          2 (−1 to 3)             0.016
  **Recall**                                            
  Pre                           6 (4 to 8)              
  Post                          7 (5 to 9)              
  Diff                          1 (0 to 2)              \<0.001
  **Recognition**                                       
  Pre                           20 (16 to 20)           
  Post                          20 (19 to 20)           
  Diff                          0 (0 to 1)              0.047
  **TMT A (sec)**                                       
  Pre                           32 (21 to 53)           
  Post                          34 (23 to 39)           
  Diff                          −2 (−6 to 2)            0.081
  **TMT B*^n^*^=19^ (sec)**                             
  Pre                           85.50 (62.25 to 118)    
  Post                          69.50 (56 to 100.75)    
  Diff                          −2.0 (−19.75 to 2.25)   0.16
  **STROOP (score) Word**                               
  Pre                           87 (72 to 67)           
  Post                          87 (80 to 103)          
  Diff                          6 (1 to 10)             \<0.001
  **Color**                                             
  Pre                           61 (52 to 67)           
  Post                          62 (54 to 69)           
  Diff                          2 (−1 to 6)             0.044
  **Word-color**                                        
  Pre                           34 (29 to 41)           
  Post                          34 (28 to 41)           
  Diff                          0 (−3 to 5)             0.67

TMT, Trail Making Test; Diff, median difference between baseline and follow up results in cognitive tests; IQR, interquartile range.

∗

The within group difference from baseline to study end.

The cognitive test scores improved in the intervention group, with improvements for CERAD learning (*p* = 0.016), recall (*p* \< 0.001) and recognition (*p* = 0.047) and for STROOP test word (*p* \< 0.001) and color (*p* = 0.044) ([Table 4](#T4){ref-type="table"} and [Supplementary Figures S5](#SM5){ref-type="supplementary-material"}--[S7](#SM7){ref-type="supplementary-material"}).

Overall, findings using parametric analyses differed only marginally from the non-parametric findings reported above ([Supplementary Tables S1](#SM8){ref-type="supplementary-material"}, [S2](#SM9){ref-type="supplementary-material"}).

The compliance was good. More than 85% of the participants returned at least 90% of the empty blister packages. The anthocyanins were well tolerated, and none of the participants withdrew due to adverse effects. Blood tests taken for safety reasons were all within a clinically acceptable range. Increased bleeding tendency was not observed.

Discussion
==========

In this pilot study anthocyanin supplementation was well tolerated, without any AE, and the compliance was good. This indicates that larger RCTs might be feasible, to confirm exploratory results in the current pilot study.

Our findings are somewhat inconclusive. While some cognitive improvements were observed in the AG, there were no significant changes in serum levels of some risk factors for dementia; i.e., fasting glucose, HbA1c or pro-inflammatory cytokines. There was a non-significant decrease in serum levels of RANTES in the AG and a non-significant increase in the NC during the study period. However, the between-group difference in Δ serum levels of RANTES was statistically significant.

Furthermore, we observed a significant increase in serum levels of total cholesterol and triglycerides in AG. The lipid profile of the NC group did not change significantly, and since we have no information about statin use or use of other lipid lowering medications in the NC group, the observed difference should be interpreted cautiously.

Previous studies using Medox^®^ have shown a statistically significant increase in HDL-cholesterol ([@B22]; [@B39]; [@B11]) and a decrease in LDL-cholesterol ([@B22]; [@B39]). This is of clinical interest, as higher HDL-cholesterol is associated with lower cardiovascular risk ([@B3]), while high levels of total cholesterol, triglycerides and LDL are associated with higher cardiovascular risk ([@B31]).

The differences in the findings between our study and these previous studies might be due to differences in participants, as well as in anthocyanin supplementation dose and duration, or other factors. Furthermore, other studies included dyslipidemic and hypercholesterolemic participants not using statins or any other lipid lowering treatment ([@B22]; [@B39]), whereas in our study, the median cholesterol at baseline in the intervention group was 4.0 mmol/l, in addition 70% were taking statins or other lipid lowering medication.

Regarding the inflammation markers, RANTES promotes activation and migration of leukocytes and mediates neuroinflammation and brain microvascular dysfunction ([@B1]; [@B4]; [@B37]). There was a significant between-group difference for ΔRANTES, although anthocyanin supplementation did not significantly reduce RANTES in the AG. Still, our results are consistent with similar findings in a randomized, double-blind trial in hypercholesterolemic individuals consuming purified anthocyanins for 24 weeks ([@B28]), and in a parallel-designed, placebo-controlled trial ([@B13]). Other studies did not report a reduction of pro-inflammatory mediators after anthocyanin supplementation ([@B11]; [@B14]). Therefore, the anti-inflammatory effect of anthocyanins and the potential to reduce neuroinflammation and brain microvascular dysfunction associated with cognitive decline in adults at risk of dementia ([@B10]) should be studied in larger randomized studies.

The beneficial effect of anthocyanins might possibly be due to their degradation products and metabolites ([@B6]) as absorption of intact anthocyanins is reported to be low ([@B38]). Rodriguez-Mateos et al. quantified metabolites in plasma after blueberry consumption, and showed that anthocyanin-derived metabolites correlated with *in vivo* effects ([@B25], [@B24]). Furthermore, circulating anthocyanin metabolites were shown to improve vascular function when injected in an *in vivo* model of vascular function, and cardiovascular benefits after consumption of anthocyanins were linked with anthocyanin metabolites as mediators of change in cellular gene programs ([@B24]).

In our study, we were able to measure a total of 29 anthocyanin metabolites. The results were conflicting, as we found various anthocyanin metabolites to be both significantly increasing and decreasing in the AG. In the NC group as well, we found significant changes. This is in line with findings in another study reporting an increase of some metabolites, and a decrease in others after ingestion of anthocyanins over time ([@B6]). A possible explanation for our results could be high inter-individual variability and the influence of the background diet on the concentration of these compounds in blood, as some of these metabolites could arise from the consumption of other anthocyanin-rich foods such as berries and red wine or other food components in the diet. It is also possible that the results could be related to the handling and analysis of the blood samples. As far as we know, the presence of anthocyanin metabolites in plasma after Medox^®^ use is reported in only one other clinical study, where 8 out of 17 anthocyanin metabolites were found to be significantly increased. However, this was analyzed in blood samples collected 1--3 h after ingestion of the morning dose of anthocyanins (320 mg), and not after daily consumption and an overnight fast ([@B11]).

The improvement on several cognitive tests should be interpreted cautiously due to potential learning effects related to the relatively short test--retest interval, and the lack of a comparison group. Nonetheless, our results are in line with previous smaller studies involving participants with MCI, reporting improved cognition after ingestion of anthocyanins ([@B15],[@B16]). Our results are also in line with the results of a randomized, double-blinded, placebo-controlled study reporting improved episodic memory after 3 months of anthocyanin supplementation ([@B33]).

Intake of anthocyanin capsules in the dosage of 320 mg/day appears to be well tolerated and safe. None of the safety blood tests were found to be out of a clinically acceptable range or necessitating medical follow-up after study-end. This is consistent with previous studies ([@B13]; [@B22]).

The major limitations of this pilot study are the non-randomized open-label design, the small sample size, and the relatively short intervention period. Although all the participants were told not to change their lifestyle during the intervention period, we have no data on this. Further we had no detailed dietary assessment, and thus we cannot exclude the possibility of differences in the background diet between the groups before or during the study. However, the participants were instructed to maintain their dietary and lifestyle habits during the study period, and to take the capsules 30 min before or 120 min after meals, as concomitant ingestion of certain types of food may counteract the effect of flavonoids ([@B18]).

The NC were recruited separately and differed from the participants by being a healthy group that did not receive any intervention, and did not perform cognitive testing. Thus power calculations for further studies might be compromised. However, we provide descriptive statistics including variance measurements which may be helpful in planning sample size in later studies.

An important strength of our study is the well characterized combination of nutraceuticals used, which facilitates comparison with other studies regarding both source of anthocyanins and dosage. Of note, this is, to our knowledge, the first study on cognitive function in adults with increased risk of dementia where Medox^®^ is being used as the source of anthocyanin. Thus our study might also facilitate investigation of the effect of different proprietary blueberry formulatons, shown by Whyte et al. to be of importance ([@B33]).

All things considered, adequately powered, randomized studies are warranted to better understand how anthocyanins and their metabolites may affect relevant mechanisms, including their possible protective role in epigenetic modifications that potentially benefit the aging brain and reduce the risk for dementia.
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Changes from baseline to 16 weeks follow-up in serum lipids, for participants with anthocyanin supplementation. mmol/L, millimole/liter.
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Changes from baseline to 16 weeks follow-up in serum fasting glucose and HbA1c, for participants with anthocyanin supplementation. HbA1a, glycosylated hemoglobin; mmol/L, millimole/liter.
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Changes from baseline to 16 weeks follow-up in serum cytokines, for participants with anthocyanin supplementation. RANTES;CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted). pg/mL, picomolar/milliliter.
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###### 

Changes from baseline to 16 weeks follow-up in plasma anthocyanin metabolites, for participants with and without anthocyanin supplementation. Measurement unit: nmol/L, nanomolar/liter, except for hippuric acid (nmol/10L) and coumaric acid-4-*O*-β-*D*-glucuronide (nmol/0.033L).
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Changes from baseline to 16 weeks follow-up in CERAD.
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Changes from baseline to 16 weeks follow-up in Trail Making Test (TMT). Sec, seconds.
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Changes from baseline to 16 weeks follow-up in Stroop test.
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###### 

Changes from baseline to 16 weeks follow-up in serum variables, for participants with supplementation (active) and for control participants. ![](fgene-10-00536-i001.jpg), mean; SD, standard deviation; ^∗^The within group difference from baseline to study end tested with paired-samples *t*-test. ^\$^independent samples *t*-test for the between group differences for Δ (difference from baseline to study end). ^\#^With Welch correction for heteroscedasticity. RANTES;CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted). Diff, mean difference between baseline and follow up results in serum measurements.
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Changes from baseline to 16 weeks follow-up in cognitive variables, for participants with supplementation (active). ![](fgene-10-00536-i001.jpg), mean; SD, standard deviation; TMT, Trail Making Test; Diff, mean difference between baseline and follow up results in cognitive tests. ^∗^The within group difference from baseline to study end tested with paired-samples *t*-test.
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